EP Patent

EP1132389A1 — New aza-indolyl derivatives for the treatment of obesity

Assigned to F Hoffmann La Roche AG · Expires 2001-09-12 · 25y expired

What this patent protects

The present invention refers to chemical compounds of formula (I); wherein X 1 , X 2 , X 3 and X 4 , n, R 1 , R 2 and R 3 and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central ne…

USPTO Abstract

The present invention refers to chemical compounds of formula (I); wherein X 1 , X 2 , X 3 and X 4 , n, R 1 , R 2 and R 3 and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1132389A1
Jurisdiction
EP
Classification
—
Expires
2001-09-12
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.